ALEC News
Archived Headlines
- US IPO Week Ahead: 2 billion-dollar biotechs in a 4-IPO week 02/01/19
- Dementia and Alzheimer's biotech Alector sets terms for $176 million IPO 01/29/19
- US IPO Weekly Recap: 2019 kicks off with IPO filings 01/11/19
- These will be the first IPOs of 2019 01/09/19
- Dementia and Alzheimer's biotech Alector files for a $150 million IPO 01/07/19
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Dementia and Alzheimer's biotech Alector prices IPO at $19, the midpoint of the range
Alector, a Phase 1 biotech developing therapies for neurodegeneration, raised $176 million by offering 9.3 million shares at $19, the midpoint of the $18 to $20 range. Alector plans to list on the Nasdaq under the symbol ALEC. Morgan Stanley, BofA Merrill...read more
2 billion-dollar biotechs will IPO this week; here's how the last 5 performed
One prediction from our 2018 Annual IPO Review is already coming true: Biotech IPOs are getting bigger. Two...read more
US IPO Weekly Recap: The SEC opens and New Fortress Energy is first through the door
With the government shutdown temporarily over, the SEC opened on Monday and IPO launches began to trickle onto the calendar, including billion-dollar biotech Alector (ALEC) and Virgin Trains USA (VTUS) . The first IPO...read more